Labcorp is reaffirming its long-term financial outlook for 2026-2029, including compound annual adjusted EPS growth of 8.5%-11.5%, despite preliminary CMS Medicare payment rates that the company believes are unrepresentative and would impose steep cuts. This suggests that the potential negative impact of these rates was already factored into their previous guidance, mitigating immediate market concern but highlighting ongoing regulatory risk.
Labcorp's 8-K filing addresses the recent release of preliminary CMS Clinical Laboratory Fee Schedule payment rates for 2027-2029. The company views these rates as potentially damaging, based on unrepresentative data, and supportive of the RESULTS Act to counter them. However, the key takeaway for investors is that Labcorp is reaffirming its previously announced 2026-2029 long-term outlook, which includes robust revenue, operating margin, and adjusted EPS growth targets. This indicates that the potential negative impact of PAMA-related reimbursement pressure was already considered in their initial guidance, suggesting that the CMS preliminary rates, while concerning, are not a new, unforeseen headwind that would necessitate a guidance revision. For traders, this filing reduces immediate uncertainty around the CMS rates' impact on Labcorp's long-term trajectory, making it a neutral to slightly positive signal as the company maintains its growth projections.